29th July 2022
Celix Pharma announces the launch of Icatibant 30mg Solution for Injection in a pre-filled syringe.
Celix Pharma is delighted to announce the launch of Icatibant 30mg Solution for Injection in a pre-filled syringe. Icatibant is available in a pack of 1 syringe, with a separate needle.
Icatibant is indicated for treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older. HAE is a rare inherited disorder characterized by recurrent episodes of the accumulation of fluids outside of the blood vessels, blocking the normal flow of blood or lymphatic fluid and causing rapid swelling of tissues in the hands, feet, limbs, face, intestinal tract, or airway (1). As a pre-filled syringe stored at ambient conditions, patients can self-administer this emergency medicine.
Commenting on this launch, Subir Kohli, Co-founder & CEO said, “Icatibant is our first injectable product on the market and the second in the rare diseases / orphan indication space (after Pirfenidone). Looking forward to working with the NHS to make this product available to patients across the country. As in the case with Pirfenidone, Icatibant will also be available through both, hospital pharmacy and directly to patients’ home via a homecare service”.
Shantreddy, Co-founder & COO added “Proud moment indeed for Celix Pharma with the launch of our first injectable product. As a peptide injectable in a pre-filled syringe, the supply chain for Icatibant is indeed complex, so happy to have navigated all the hurdles successfully to bring this challenging product to market.”
1. Source: National Organisation for Rare Disorders (https://rarediseases.org/rare-diseases/hereditary-angioedema/)
About Celix Pharma Ltd
Celix Pharma is a London-based generic pharmaceutical company founded in 2020 with an overarching goal to bring high quality, affordable, generic medicines with a sustainable supply chain to the UK. Celix Pharma focuses on bridging gaps in the market by identifying product opportunities arising from complexities in development and/or manufacturing, addressing supply disruptions and future patent expiries. Celix Pharma is building a portfolio across both, primary-care and secondary-care, with a range of generics, branded generics, and hospital specialty products. Celix Pharma’s business model is built around creating a commercially-led, customer-focused organization supported with strategic partnerships in R&D and manufacturing.
For more information, visit www.celixpharma.com